drugset / Trial / NCT02206607

Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.

NCT02206607

Phase 1 Completed 39 enrolled Pfizer
RandomizedCrossoverOpen-labelBasic science

Summary

Study B1621015 will characterize bioavailability, tolerability and pharmacodynamics of three modified release formulations of PF-04937319 compared with the immediate release material-sparing-tablet (IR MST) formulation in adults with type 2 diabetes.

Timeline

Start
2014-09
Primary completion
2015-01
Completion
2015-01

Drugs

EvaluationDrugModalityDoseRoute
Subject NERIGLIATIN Small molecule 100 mg Oral
Subject NERIGLIATIN Small molecule 150 mg Oral